Metformin treatment response is dependent on glucose growth conditions and metabolic phenotype in colorectal cancer cells

[1]  B. Gago,et al.  Translational Challenges , 2021, Nanoparticles for Brain Drug Delivery.

[2]  Ji-lin Wang,et al.  Metformin elicits antitumour effect by modulation of the gut microbiota and rescues Fusobacterium nucleatum-induced colorectal tumourigenesis , 2020, EBioMedicine.

[3]  T. Kim,et al.  Metformin Suppresses Cancer Stem Cells through AMPK Activation and Inhibition of Protein Prenylation of the Mevalonate Pathway in Colorectal Cancer , 2020, Cancers.

[4]  N. Sata,et al.  Metformin changes the immune microenvironment of colorectal cancer in patients with type 2 diabetes mellitus , 2020, Cancer science.

[5]  P. Tsichlis,et al.  A phase I delayed-start, randomized and pharmacodynamic study of metformin and chemotherapy in patients with solid tumors , 2019, Cancer Chemotherapy and Pharmacology.

[6]  Bernhard X. Kausler,et al.  ilastik: interactive machine learning for (bio)image analysis , 2019, Nature Methods.

[7]  Fred A. Hamprecht,et al.  ilastik: interactive machine learning for (bio)image analysis , 2019, Nature Methods.

[8]  Jaw-Yuan Wang,et al.  High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy , 2019, Therapeutic advances in medical oncology.

[9]  J. Bradley,et al.  Initial reporting of NRG-LU001 (NCT02186847), randomized phase II trial of concurrent chemoradiotherapy (CRT) +/- metformin in locally advanced Non-Small Cell Lung Cancer (NSCLC). , 2019, Journal of Clinical Oncology.

[10]  P. Waterhouse,et al.  Identifying the murine mammary cell target of metformin exposure , 2019, Communications Biology.

[11]  F. Azuaje,et al.  Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis , 2019, Acta neuropathologica communications.

[12]  Renquan Zhang,et al.  Metformin Use and Lung Cancer Risk in Diabetic Patients: A Systematic Review and Meta-Analysis , 2019, Disease markers.

[13]  M. Stuschke,et al.  Metformin enhances the radiosensitizing effect of cisplatin in non-small cell lung cancer cell lines with different cisplatin sensitivities , 2019, Scientific Reports.

[14]  B. Faubert,et al.  Metabolic diversity in human non-small cell lung cancer , 2014, bioRxiv.

[15]  Fergus Gleeson,et al.  Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer , 2018, Cell metabolism.

[16]  P. Siegel,et al.  Metabolic Profiles Associated With Metformin Efficacy in Cancer , 2018, Front. Endocrinol..

[17]  R. Fulbright,et al.  Deuterium metabolic imaging (DMI) for MRI-based 3D mapping of metabolism in vivo , 2018, Science Advances.

[18]  Young Seol Kim,et al.  Metformin reduces the risk of cancer in patients with type 2 diabetes , 2018, Medicine.

[19]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[20]  J. H. Kim,et al.  Effects of metformin on colorectal cancer stem cells depend on alterations in glutamine metabolism , 2018, Scientific Reports.

[21]  R. Gillies,et al.  Metabolic Profiling of healthy and cancerous tissues in 2D and 3D , 2017, Scientific Reports.

[22]  Jamey D. Young,et al.  Lactate Metabolism in Human Lung Tumors , 2017, Cell.

[23]  M. V. Vander Heiden,et al.  Targeting Metabolism for Cancer Therapy. , 2017, Cell chemical biology.

[24]  Shan Tian,et al.  The association between metformin use and colorectal cancer survival among patients with diabetes mellitus: An updated meta-analysis , 2017, Chronic diseases and translational medicine.

[25]  S. Pirkmajer,et al.  Combined treatment with Metformin and 2-deoxy glucose induces detachment of viable MDA-MB-231 breast cancer cells in vitro , 2017, Scientific Reports.

[26]  S. Jong,et al.  Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells , 2017, BMC Cancer.

[27]  N. Liao,et al.  An updated meta-analysis , 2017 .

[28]  Hua Yu,et al.  Metabolic reprogramming and AMPKα1 pathway activation by caulerpin in colorectal cancer cells. , 2017, International journal of oncology.

[29]  R. Langley,et al.  Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  N. Hay,et al.  Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? , 2016, Nature Reviews Cancer.

[31]  M. Brand,et al.  Determining Maximum Glycolytic Capacity Using Extracellular Flux Measurements , 2016, PloS one.

[32]  Hao Liu,et al.  Metformin suppresses hypoxia-induced stabilization of HIF-1α through reprogramming of oxygen metabolism in hepatocellular carcinoma , 2015, Oncotarget.

[33]  S. Brandhorst,et al.  Fasting and Caloric Restriction in Cancer Prevention and Treatment. , 2016, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[34]  A. Paranjape,et al.  Glucose transporters: physiological and pathological roles , 2016, Biophysical Reviews.

[35]  Takla Griss,et al.  Metformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis , 2015, PLoS biology.

[36]  R. DeFronzo,et al.  The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies , 2015, Diabetes Care.

[37]  L. Prokop,et al.  Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies , 2015, Scientific Reports.

[38]  O. Olopade,et al.  Metformin for primary colorectal cancer prevention in patients with diabetes: A case‐control study in a US population , 2015, Cancer.

[39]  S. Cho,et al.  Antihyperglycemic mechanism of metformin occurs via the AMPK/LXRα/POMC pathway , 2015, Scientific Reports.

[40]  J. Ioannidis,et al.  Metformin Does Not Affect Cancer Risk: A Cohort Study in the U.K. Clinical Practice Research Datalink Analyzed Like an Intention-to-Treat Trial , 2014, Diabetes Care.

[41]  M. Pollak,et al.  Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria , 2014, The Biochemical journal.

[42]  L. Boros,et al.  Metformin and Pancreatic Cancer Metabolism , 2014 .

[43]  Hao Wu,et al.  Beyond Warburg effect – dual metabolic nature of cancer cells , 2014, Scientific Reports.

[44]  Andrea Glasauer,et al.  Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis , 2014, eLife.

[45]  D. Sabatini,et al.  Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides , 2014, Nature.

[46]  R. Riechelmann,et al.  A phase II trial of metformin and fluorouracil (MetFU) for patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard treatment. , 2014 .

[47]  Mark F. Lythgoe,et al.  In vivo imaging of glucose uptake and metabolism in tumors , 2012, Nature Medicine.

[48]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[49]  R. Deberardinis,et al.  Metabolism of [U‐13C]glucose in human brain tumors in vivo , 2012, NMR in biomedicine.

[50]  Sephra N. Rampersad,et al.  Multiple Applications of Alamar Blue as an Indicator of Metabolic Function and Cellular Health in Cell Viability Bioassays , 2012, Sensors.

[51]  B. Martín-Castillo,et al.  Metformin is synthetically lethal with glucose withdrawal in cancer cells , 2012, Cell cycle.

[52]  A. Khurana,et al.  Metformin is synthetically lethal with glucose withdrawal in cancer cells , 2012, Cell cycle.

[53]  Saroj Niraula,et al.  Metformin in cancer: translational challenges. , 2012, Journal of molecular endocrinology.

[54]  T. Tsakiridis,et al.  Expression of the glucose transporters GLUT1, GLUT3, GLUT4 and GLUT12 in human cancer cells , 2012, BMC Proceedings.

[55]  Ruud P. M. Dings,et al.  Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells , 2012, Scientific Reports.

[56]  G. Hortobagyi,et al.  Effect of metformin on survival outcomes in diabetic patients with triple receptor‐negative breast cancer , 2012, Cancer.

[57]  B. Viollet,et al.  Cellular and molecular mechanisms of metformin: an overview. , 2012, Clinical science.

[58]  J. Scannell,et al.  Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.

[59]  Timothy J. Mitchison,et al.  The proliferation rate paradox in antimitotic chemotherapy , 2012, Molecular biology of the cell.

[60]  R. Rocha,et al.  CLINICS 2011;66(6):965-972 DOI:10.1590/S1807-59322011000600008 CLINICAL SCIENCE , 2022 .

[61]  R. Day,et al.  Clinical Pharmacokinetics of Metformin , 2011, Clinical pharmacokinetics.

[62]  E. Negelein,et al.  THE METABOLISM OF CARCINOMA CELLS , 2011 .

[63]  Keshav K. Singh,et al.  Cellular stress induced by resazurin leads to autophagy and cell death via production of reactive oxygen species and mitochondrial impairment , 2010, Journal of cellular biochemistry.

[64]  Massimiliano Cazzaniga,et al.  Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis , 2010, Cancer Prevention Research.

[65]  P. Donnan,et al.  New Users of Metformin Are at Low Risk of Incident Cancer , 2009, Diabetes Care.

[66]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[67]  C. Bailey,et al.  Metformin and the intestine , 2008, Diabetologia.

[68]  P. Mahadevan,et al.  An overview , 2007, Journal of Biosciences.

[69]  J. Best,et al.  Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer , 2005, Journal of cellular physiology.

[70]  W. R. Lieb,et al.  Kinetic parameters of glucose efflux from human red blood cells under zero-trans conditions. , 1972, Biochimica et biophysica acta.

[71]  O. Warburg,et al.  The Metabolism of Carcinoma Cells , 1925 .